Literature DB >> 103767

Plasma arginine vasopressin in diabetic ketoacidosis.

C H Walsh, P H Baylis, J M Malins.   

Abstract

Plasma Arginine Vasopressin (AVP) was measured serially in 10 patients during the first 24 hours of treatment of diabetic ketoacidosis. AVP was elevated in all cases initially, ranging from 4.0--122.0 pmol/l, the basal level in healthy hydrated subjects being 1.57 +/- 0.59 pmol/l (+/- 1 SD). The levels fell progressively during the course of treatment. While there was no evidence that the massive increases in AVP noted in this study were associated with water overload it remains to be determined whether the high levels observed have any significant metabolic or haemodynamic role in this disorder.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 103767     DOI: 10.1007/bf01225456

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  Fatal Diabetic Ketosis.

Authors:  M G Fitzgerald; D J O'Sullivan; J M Malins
Journal:  Br Med J       Date:  1961-01-28

2.  The development of a radioimmunoassay for the measurement of human plasma arginine vasopressin.

Authors:  P H Baylis; D A Heath
Journal:  Clin Endocrinol (Oxf)       Date:  1977-08       Impact factor: 3.478

Review 3.  Vasopressin in osmotic regulation in man.

Authors:  G L Robertson
Journal:  Annu Rev Med       Date:  1974       Impact factor: 13.739

4.  Stimulation of ADH release by the renin-angiotensin system.

Authors:  J P Bonjour; R L Malvin
Journal:  Am J Physiol       Date:  1970-06

5.  Cerebral edema, diabetes insipidus, and sudden death during the treatment of diabetic ketoacidosis.

Authors:  H Taubin; R Matz
Journal:  Diabetes       Date:  1968-02       Impact factor: 9.461

Review 6.  The regulation of vasopressin function in health and disease.

Authors:  G L Robertson
Journal:  Recent Prog Horm Res       Date:  1976

7.  Cerebral edema complicating therapy for diabetic ketoacidosis.

Authors:  S C Duck; V V Weldon; A S Pagliara; M W Haymond
Journal:  Diabetes       Date:  1976-02       Impact factor: 9.461

8.  Plasma renin activity and blood volume in uncontrolled diabetes. Ketoacidosis, a state of secondary aldosteronism.

Authors:  A R Christlieb; J P Assal; N Katsilambros; G H Williams; G P Kozak; T Suzuki
Journal:  Diabetes       Date:  1975-02       Impact factor: 9.461

9.  The effect of pain on plasma arginine vasopressin concentrations in man.

Authors:  K S Kendler; R E Weitzman; D A Fisher
Journal:  Clin Endocrinol (Oxf)       Date:  1978-02       Impact factor: 3.478

  9 in total
  8 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Vasopressin and diabetic ketoacidosis.

Authors:  P J Grant; P G Wiles; J A Davies; C R Prentice
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

3.  The hypothalamo-neurohypophysial system in streptozotocin-diabetic rats: ultrastructural and immunocytochemical evidence for alterations of oxytocin- and vasopressin-containing neuronal profiles.

Authors:  A Loesch; J Lincoln; G Burnstock
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 4.  The endocrine system in diabetes mellitus.

Authors:  Hisham Alrefai; Hisham Allababidi; Shiri Levy; Joseph Levy
Journal:  Endocrine       Date:  2002-07       Impact factor: 3.633

5.  Interactions between vasopressin and glucagon on ketogenesis and oleate metabolism in isolated hepatocytes from fed rats.

Authors:  D H Williamson; V Ilic; A F Tordoff; E V Ellington
Journal:  Biochem J       Date:  1980-02-15       Impact factor: 3.857

6.  PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes.

Authors:  Ramzi Hassouneh; Rania Nasrallah; Joe Zimpelmann; Alex Gutsol; David Eckert; Jamie Ghossein; Kevin D Burns; Richard L Hébert
Journal:  Diabetologia       Date:  2016-03-19       Impact factor: 10.122

7.  Enhanced expressions of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats.

Authors:  Sun Shin Yi; In Koo Hwang; Yo Na Kim; Il Yong Kim; Son-Il Pak; In Se Lee; Je Kyung Seong; Yeo Sung Yoon
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

8.  Plasma vasopressin during insulin withdrawal in insulin-dependent diabetes.

Authors:  J J Milles; P H Baylis; A D Wright
Journal:  Diabetologia       Date:  1981-06       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.